Compare POET & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | POET | HQL |
|---|---|---|
| Founded | 1972 | 1992 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Investment Managers |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.2M | 510.2M |
| IPO Year | N/A | N/A |
| Metric | POET | HQL |
|---|---|---|
| Price | $6.11 | $16.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 8.0M | 120.9K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $762,695.00 | N/A |
| Revenue This Year | $2,939.08 | N/A |
| Revenue Next Year | $710.17 | N/A |
| P/E Ratio | ★ N/A | $17.08 |
| Revenue Growth | ★ 535.87 | N/A |
| 52 Week Low | $3.09 | $11.34 |
| 52 Week High | $9.41 | $14.37 |
| Indicator | POET | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 43.96 |
| Support Level | $5.81 | $17.03 |
| Resistance Level | $6.59 | $17.25 |
| Average True Range (ATR) | 0.56 | 0.31 |
| MACD | 0.06 | -0.09 |
| Stochastic Oscillator | 52.46 | 14.29 |
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.